ClinicalTrials.gg
RecruitingNCT05981534Updated Mar 27, 2024

The Effectiveness of Vitamin D Supplementation in Patients With End-stage Knee Osteoarthritis

An interventional study of Vitamin D and Placebo in Vitamin D Deficiency, Sarcopenia and Knee Osteoarthritis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies testing Vitamin D in Vitamin D Deficiency — 15 open to participants now, 16 under way, none of them phase 3. Vitamin D · Vitamin D Deficiency.

Planned enrollment
91st of 153
56 · median 75
Started
2024
with 6 others
No phase
87 of 154
12 open now
Primary completion
2025-06
later than 4 of 15 live
Registered
142nd of 154
by date

Among the 154 studies testing Vitamin D in Vitamin D Deficiency, this one is the 91st largest by planned enrollment of the 153 interventional ones that give a count, is one of 7 that started in 2024, is one of 87 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 142nd registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

15 of the 154 studies testing Vitamin D in Vitamin D Deficiency are open now, in 8 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About Vitamin D

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies testing Vitamin D in Vitamin D Deficiency, or all of them as a file.
02

Study summary

Osteoarthritis (OA) knee is one of the commonest chronic degenerative conditions. It causes disability in elderlies due to pain and stiffness. The prevalence of radiologic knee osteoarthritis increases in proportion to age, reaching an astounding 64.1% for patients who are over 60 years of age. In 2021, there were over 26,000 patients on the Hospital Authority (HA) waiting list for knee total knee replacement (TKR) and with only 4300 TKRs performed, the nominal waiting time for TKR was almost 89 months.

Low vitamin D can adversely affect cartilage thickness and study suggested that low serum vitamin D is associated with increased radiographic knee OA progression. A systematic review concluded that vitamin D supplements can improve pain and function in patients with knee OA.

Vitamin D has long been recognized for its effect on musculoskeletal health and increasing attention has been focused for its effect on muscle function. Vitamin D have a direct effect on muscle hypertrophy by acting on specific vitamin D receptors (VDRs) on myocytes, and sufficient levels of vitamin D in patients have been found to correlate with an increase in the size, number, and strength of muscle fibres. Vitamin D also seems to exert beneficial effects by its interplay with myokines such as myostatin and irisin.

One study also showed that muscle nuclear VDR was increased by 30% and augmented muscle fibre size by 10% in elderly females (mean age of 78 years) taking vitamin D orally at a rate of 100 µg/day (4000 IU/day) for 4 months.

This will be a double-blinded RCT investigating the effect of vitamin D supplements or knee muscle strength, physical function, pain symptoms and, sarcopenia status. The study will be a follow-up study with assessment at baseline, 3- ,6-and 12-months post vitamin D intervention.

Read the detailed description

Osteoarthritis (OA) knee is one of the common chronic degenerative conditions. It causes disability in elders, leading to pain and stiffness. The prevalence of radiologic knee osteoarthritis and symptomatic knee OA were 37.4% and 12.1% among adults over 60 years of age.

Often, patients with end-stage knee OA often adopt a sedentary lifestyle to avoid joint pain and stiffness. This can have an adverse effect on muscle function both locally around the knees as well as on generalized muscle health. Ageing and inactivity leads to a progressive loss of muscle mass and strength until an abnormally low level, termed "sarcopenia". Sarcopenic elderlies are more likely to develop deterioration of functional outcomes and higher mortality resulting in socioeconomic and healthcare burdens. In contrast, our previous study investigating the prevalence of sarcopenia in end-stage OA showed that 32.8% of severe knee OA patients also suffered sarcopenia, and these patients showed a slower recovery after undergoing TKR.

Vitamin D has long been recognized for its effect on musculoskeletal health, and increasing attention has been focused on its effect on muscle function. Vitamin D directly affects muscle hypertrophy by acting on specific vitamin D receptors (VDRs) in myocytes, and sufficient vitamin D levels in patients have been found to correlate with an increase in the size, number, and strength of muscle fibers. In the Chinese population aged over 65, 30.6% of the population studied presented with vitamin D deficiency (25(OH)D \<20 ng/mL). A systematic review concluded that vitamin D supplements can improve pain and function in patients with knee OA. Moreover, patients with end stage OA knees will have more pain, leading to decreased mobility, a higher risk of sarcopenia, and vitamin D insufficiency that would warrant attention.

56 patients with end-stage knee OA scheduled for TKR will be recruited from the Li Ka Shing Orthopaedic Specialist clinic at the Prince of Wales Hospital (PWH) Hong Kong.

Oral and written consents will be obtained from individuals who agree to participate in the study.

The recruitment period will last for 12 months and the whole project period is 2 years in total. Basic demographics, sarcopenia assessment and Outcome Measurement Questionnaires will be carried out. The patients will be advised to avoid taking supplements and keep a record of medication intake throughout the study period.

We will use 4000 IU/day, for 6 months adapted from previous study. All study tablets including the placebo will be manufactured according to Good Manufacturing Practice (GMP) guidelines for quality assurance.

Assessments including quadriceps and hamstring muscle strength, handgrip strength, 6-meter timed walking gait test, chair stand test, muscle mass using Dual Energy X-ray Absorptiometry and questionnaires will be conducted.

03

Conditions studied

  • Vitamin D Deficiency
  • Sarcopenia
  • Knee Osteoarthritis

Keywords

  • Vitamin D
  • Sarcopenia
  • Muscle atrophy
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged over 50 with end-stage knee OA
  • Patient are on the waiting list for TKR at Prince of Wales Hospital
  • Walk unaided for 6 meters
  • Able to comply with the assessments and has given oral and written consent
  • Patients with vitamin D insufficiency and deficiency at the baseline measurement (25(OH)D \<30 ng/mL)

Exclusion criteria

Exclusion Criteria:

  • Patients with connective tissue disorders or myositis condition
  • History of any Hip \& Knee surgery
  • Patients with malnutrition were assessed by Mini-Nutritional assessment.
  • Patients with acute immobility (i.e., post-hip fracture or post-acute hospital admission)
  • Patient scheduled for TKR within six months
  • Patients already taking vitamin D supplements
  • Patients with a known to vitamin D treatment (such as allergy)
  • Patients who have renal impairment with (eGFR) \< 30 ml/minute
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The intervention group will receive vitamin D supplement for 6 months

    Drug: Vitamin D

  • Placebo comparator
    Control group

    The control group will receive placebo for 6 months

    Drug: Placebo

Interventions

  • 4000IU/day vitamin D supplement will be used for 6 months

    Also known as: SODX Co., Ltd, Osaka, Japan

  • DrugPlacebo

    Placebo will be used for 6 months

    Also known as: SODX Co., Ltd, Osaka, Japan

06

What researchers measure

Primary outcomes

  1. Quadriceps and hamstring muscle strength assessment

    Hand-held dynamometer microFET2 (Hoggan Scientific, Salt Lake City UT, USA) will be used to assess lower limb strength and power. Assessment of isometric muscle strength and power will be performed with the participants in a seated position to assess knee extensors and knee flexors. All tests will involve maximal voluntary isometric contractions. Both limbs will be assessed to record side-to-side difference. Two trials were recorded for each muscle group.

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

Secondary outcomes

  1. The 6-meter timed walking test

    The 6-meter timed walking test is a well-established test to assess gait speed. However, due to space limitations and the exhaustive nature of the test for patients with OA, the 6-meter test has been documented to be a valid and reliable substitute. Patients will be asked to walk a straight line of 6 meters where the time taken to complete the distance will be measured. (\<7.5 seconds is normal).

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  2. 5-time Chair stand test

    The chair stand test is a reliable test for assessment for low limb strength in patients. Patients will be asked to sit on a solid chair with arms on shoulders and feet with shoulder width apart. They will be instructed to do 1-2 repetitions to become familiar with the test, and perform as many reputations as they can in 30 seconds.

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  3. Dual Energy X-ray Absorptiometry (DXA)

    The radiation for one session (20 minutes) for sarcopenia assessment is less than 25µSv, which is within the safe range. After every DXA scan, two copies will be printed that show the patients' body composition, bone mineral density, fat percentage, body mass index, and most importantly for this study, lean muscle mass.

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    It is a questionnaire that measures a patient's pain, stiffness and physical function and can be summed up into a score out of 96. A high score indicates a more disabled participant .

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  5. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    To to evaluate symptoms and function in patients with knee injury and osteoarthritis with five separately scored subscales. Higher scores means better knee function

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  6. Short-Form 36 (SF-36)

    36 questions to measure a patient's functional health and well-being from a patient's point of view. It is a reliable and validated measure that summarises the patients' physical and mental health. Higher scores means better quality of life.

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  7. International Physical Activity Questionnaire (IPAQ)

    Assesses and monitors a patient's physical activity and inactivity level. This instrument sums up a patient's activity level per week into three categories, Category 1 Inactivity, category 2 minimally active and category 3 HEPA active

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  8. Nutritional intake questionnaire

    Evaluation of habitual dietary intake will be based on retrospective means of assessment for the past twelve months. A Food Frequency Questionnaire (FFQ) previously validated with data obtained in the Hong Kong Adult Dietary Survey in 1995 as described previously will be used(Appendix 7). Daily dietary intake of Vitamin D and calcium will be evaluated by the Food Processor Nutrition Analysis and Fitness software version 7.9 (Esha Research, Salem, USA), with incorporation of local food composition based on food composition table from China

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  9. Sunlight exposure questionnaire

    The Chinese version of the sunlight exposure questionnaire will be used in this study and has proven to be adequate for measurement of lifetime sunlight exposure among Hong Kong Chinese women. Higher scores means high chance of level vitamin D level.

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  10. Handgrip strength

    The handgrip dynamometer will be used to test for the patients' handgrip strength. The handgrip dynamometer is an instrument measuring patients' maximum isometric strength of the hand and forearm muscles. The handle of the dynamometer will be adjusted as the finger is at 90 o whilst the dynamometer is being held. The measurement will be repeated three times and the average calculated for the dominant hand (Hand dominance will be determined by observing the patient's writing hand when signing the informed consent).

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  11. Serum myokine evaluation

    Blood taking (5 ml) will be performed. The serum will be prepared by centrifugation and kept in a -80º freezer until use. Quantitative analysis for myokines and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities) or enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

  12. Serum vitamin D assays

    Serum 25(OH)Vit-D levels will be measured by a commercial 25(OH) Vitamin D ELISA kit (Abcam ab213966) according to the manufacturer's instruction, providing the quantitative determination of 25(OH) Vitamin D3 and 25(OH) Vitamin D2

    Time frame: Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: starting 6 months after publication

Access criteria: Journal reviewer

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 15 months after the start.

Of 167 non-industry interventional studies with no phase under Vitamin D Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 15 months is above that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 4 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 8, 2023
StartActual
Mar 17, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981534
Responsible party
Prof. Tim-Yun Michael ONG (Clinical Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Aug 8, 2023
Start date
Mar 17, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Mar 27, 2024

Study contacts

Michael Tim-Yun ONG, MSc
Contact
michael.ong@cuhk.edu.hk
26364171
26364171 ONG, MSc
Contact
michael.ong@cuhk.edu.hk
26364171
Michael Tim-Yun ONG
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion